Therefore, there is a clinical need to identify therapies that enhance progestin sensitivity by upregulating PR, downregulating obesity-related factors, and inhibiting the PI3K/AKT pathway. This evidence concerns the gene PGR and obesity due to melanocortin 4 receptor deficiency.